RxDoctor Payments Data

Dinesh Bhatia, MD

Nephrology · Atlanta, GANPI 1407941008

Payments from drug & device makers

$3,761in general payments, 2019–2025

Across 188 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$933
  • Otsuka America Pharmaceutical, Inc.$540
  • AstraZeneca$376
  • Akebia Therapeutics Inc$361
  • Bayer$283
  • Vifor Pharma, Inc.$192
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,61796%
  • Education$1444%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,761 in reported general payments places this provider in the 65th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$285,345
Medicare patients
470
Services billed
4,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol255$204,114
JardianceEmpagliflozin83$78,608
LokelmaSodium Zirconium Cyclosilicate32$20,730
OzempicSemaglutide16$19,630
KerendiaFinerenone18$16,916
Cinacalcet Hcl24$16,261
VascepaIcosapent Ethyl38$10,565
DapagliflozinDapagliflozin Propanediol20$10,433
InvokanaCanagliflozin12$6,755
EdarbyclorAzilsartan Med/Chlorthalidone24$5,661
MyrbetriqMirabegron11$4,933
Breo ElliptaFluticasone/Vilanterol12$4,728
Tresiba Flextouch U-100Insulin Degludec11$4,487
Hydralazine Hcl185$3,310
Allopurinol290$3,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$376$224,845287 claims
Boehringer IngelheimJardiance$14$78,60883 claims
Novo NordiskOzempic$12$19,63016 claims
BayerKerendia$283$16,91618 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$17$8,48535 claims
Johnson & JohnsonInvokana$12$6,75512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 nephrology providers in Georgia.

Other nephrology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →